Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06872021

Early Intra-aortic Balloon Pump Use After Venoarterial Extracorporeal Membrane Oxygenation: The EASE-ECMO Randomized Clinical Trial

Led by Beijing Anzhen Hospital · Updated on 2026-03-24

358

Participants Needed

1

Research Sites

13 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effect of early use of an Intra-aortic Balloon Pump (IABP) for left ventricular unloading in patients with cardiogenic shock who are receiving venoarterial extracorporeal membrane oxygenation (VA-ECMO). This multicenter, randomized trial aims to determine whether early IABP use improves outcomes compared to the conventional approach without mechanical unloading. The study will include 358 patients to assess the impact on 30-day mortality and other clinical outcomes. Participants will be randomly assigned to one of two groups: the ECMO+IABP group, receiving IABP within 6 hours after VA-ECMO starts, or the ECMO group, which will not receive mechanical unloading within 6 hours. The main focus is on early intervention to unload the left ventricle in patients undergoing VA-ECMO treatment for cardiogenic shock. During the study, researchers will monitor participants for 30 days, measuring mortality, ability to wean from VA-ECMO, left ventricular function, rates of complications such as stroke, bleeding, infections, and length of hospital and intensive care stays. Various laboratory markers and imaging outcomes will also be evaluated to assess heart function and recovery. The trial intends to provide detailed information on the benefits and risks of early IABP use in this patient population.

CONDITIONS

Brief Title

Early Intra-aortic Balloon Pump Use After Venoarterial Extracorporeal Membrane Oxygenation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age of 18 years or older
  • Diagnosis of cardiogenic shock defined by low blood pressure, high arterial lactate, and signs of poor organ perfusion
  • Successful implantation of venoarterial extracorporeal membrane oxygenation (VA-ECMO)
  • Provided informed consent to participate
Not Eligible

You will not qualify if you...

  • SCAI shock stage A or B
  • Moderate to severe aortic valve leakage or aortic dissection
  • Severe peripheral vascular disease
  • Cardiogenic shock after heart surgery (non-CABG) or bridging to heart transplant or LVAD
  • VA-ECMO used for non-cardiac causes
  • Isolated right ventricular failure
  • VA-ECMO use limited to during surgery or interventions
  • Ischemic mechanical complications like ventricular septal defect or papillary muscle rupture
  • Extracorporeal cardiopulmonary resuscitation
  • Existing LVAD, Impella, or IABP device in place
  • Severe bleeding
  • Terminal cancer
  • Irreversible neurologic injury
  • Pregnancy or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 30 days

Participants receive venoarterial extracorporeal membrane oxygenation (VA-ECMO). Early intra-aortic balloon pump (IABP) use for left ventricular unloading is initiated within 6 hours after VA-ECMO start for those in the experimental group. Those in the comparator group do not receive mechanical unloading within 6 hours.

Ongoing care during hospitalization with assessments as part of treatment

Follow-up

Duration - Up to 30 days after treatment start

Participants are monitored for outcomes including mortality, weaning from VA-ECMO, cardiac function, complications, and length of hospital stay through 30 days after treatment initiation.

Assessments during hospitalization and follow-up visits as needed

Trial Site Locations

Total: 1 location

1

Beijing Anzhen Hospital

Beijing, Beijing Municipality, China, 100029

Actively Recruiting

Loading map...

Research Team

X

Xiaotong Hou, MD, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Influence of a Personalized Lung Volume Optimization Maneuve...

Congenital Heart Disease

Actively Recruiting

1 location

Super-Early Neuroprognostication in eCPR Patients: Feasibili...

Resuscitation

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here